PCV142 a Review of the Primary Care Prescribing of Dabigatran Etexilate and Rivaroxaban in Ireland

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.861
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Cost-Effectiveness of Apixaban Compared to Warfarin, Aspirin, Rivaroxaban and Dabigatran in Ireland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

The Cost-Effectiveness of Dabigatran Etexilate Compared With Rivaroxaban in the Treatment of Acute Venous Thromboembolism in the Uk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

New Options With Dabigatran Etexilate in Anticoagulant Therapy

Vascular Health and Risk Management
2010English

Trends in Anticoagulant Prescribing: A Review of Local Policies in English Primary Care

BMC Health Services Research
Health Policy
2020English

Dabigatran Compared With Rivaroxaban vs Warfarin

JAMA Internal Medicine
Internal Medicine
2017English

Two and Half Years With Dabigatran Etexilate in Neurological Units

Journal of Vascular Medicine & Surgery
2013English

Factors Associated With the Prescribing of High-Dose Opioids in Primary Care: A Systematic Review and Meta-Analysis

BMC Medicine
Medicine
2020English

An Unusual Side Effect of Dabigatran Etexilate Use - Acute Renal Failure

Eurasian Journal of Emergency Medicine
2019English

Oral Antithrombotic Inhibitors: Dabigatran Etexilate, Meeting an Unmet Need?

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy